Expansion of Overseas Sales of Pharmaceutical and Health-Related Products
First written in FY2016-Q2. 32 of 37 entries say "Advanced", first in FY2016-Q3. Latest entry: 2026-07-31.
96 other companies' latest entry also says "Advanced".
- 2026-07-31AdvancedEarnings
「Overseas, initiatives to enhance brand value proved effective, and sales volumes increased, particularly in the Philippines and Vietnam.」
The company described overseas POCARI SWEAT brand initiatives and growth in sales volumes. - FY2026-H1AdvancedAnnual report
「Overseas, initiatives to enhance brand value proved effective, and sales volumes increased, particularly in the Philippines and Vietnam.」
The disclosure states that overseas initiatives to enhance Pocari Sweat's brand value led to higher sales volumes in the Philippines and Vietnam. - 2026-04-28AdvancedEarnings
「Overseas, initiatives to enhance brand value proved effective and sales volumes remained firm, with particularly strong growth in the Philippines and Vietnam.」
For overseas sales of products including POCARI SWEAT, the company specifically described growth in sales volumes in the Philippines and Vietnam. - FY2025AdvancedAnnual report
「As new markets, the company began full-scale sales in India in July 2025 and in Nigeria in November.」
Pocari Sweat began full-scale sales in India and Nigeria, expanding its international footprint. - FY2025-H1AdvancedAnnual report
「Aripiprazole two-month long-acting injectable Abilify Asimtufii generated a substantial increase in revenue in the US and Europe as prescriptions grew through efforts to communicate the product's benefits, information-provision activities and switches from the one-month formulation, aripiprazole long-acting injectable Abilify Maintena. As a result, revenue was ¥16.163 billion, up 114.2% year on year.」
Prescribing of the two-month formulation expanded in the US and Europe, and switches from the one-month formulation progressed, resulting in a 114.2% year-on-year increase in revenue. - FY2024AdvancedAnnual report
「Revenue for the consolidated fiscal year increased, mainly in the medical-related and nutraceuticals-related businesses, to ¥2,329.861 billion, up 15.4% year on year.」
Higher domestic and overseas revenue from global products including Rexulti, Lonsurf, Abilify Maintena/Asimtufii and JINARC, as well as nutraceuticals-related products, contributed to the company's overall revenue growth. - FY2024-Q1AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotics Abilify Maintena/Abilify Asimtufii, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥199.741 billion, up 25.1% year on year.」
Combined revenue from the four global products, including overseas revenue, increased 25.1% year on year. The disclosure also cites approval in Europe of the two-month long-acting injectable and expanded prescribing in the US and Europe. - FY2023AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥726.850 billion, up 17.4% year on year.」
Revenue from the four global products was ¥726.850 billion, up 17.4% year on year. Approvals for additional indications and sales expansion in the US and Europe are also progressing. - FY2023-Q3AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥527.977 billion, up 16.2% year on year.」
Combined revenue from the four global products was ¥527.977 billion, up 16.2% year on year. Information-provision activities, additional indications and expanded prescribing and sales overseas are progressing for each product. - FY2023-Q2AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥337.138 billion, up 15.8% year on year.」
Combined revenue from the four global products was ¥337.138 billion, up 15.8% year on year, indicating progress in product development, including expanded approvals, prescribing and sales overseas. - FY2023-Q1AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥159.678 billion, up 17.8% year on year.」
Combined revenue from the four global products increased 17.8% year on year. The disclosure cites disease awareness and information-provision activities for JINARC, and face-to-face information-provision activities and other initiatives to expand prescribing for Abilify Maintena and Rexulti. - FY2022AdvancedAnnual report
「Combined revenue from the four products designated by our Group as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥619,187 million, up 26.4% from the previous fiscal year.」
Combined revenue from the four global products increased 26.4% year on year to ¥619.187 billion, driven by the expansion of prescribing and sales overseas. - FY2022-Q3AdvancedAnnual report
「In the United States, prescriptions for ADPKD treatment increased through ongoing disease-awareness activities and the provision of clinical data and other information, and revenue increased substantially, partly due to foreign exchange effects. As a result, revenue increased 34.5% year on year to ¥99,931 million.」
For Jinarc, prescriptions increased in the United States through disease-awareness and information activities, resulting in a 34.5% year-on-year increase in revenue. - FY2022-Q2AdvancedAnnual report
「Combined revenue from the four products designated by our Group as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥291,165 million, up 23.4% year on year.」
Combined revenue from the four global products was ¥291,165 million, up 23.4% year on year. Increases in prescriptions, information activities, additional indications, and progress in overseas sales are noted for each product. - FY2022-Q1AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥135,602 million, up 18.0% year on year.」
Combined revenue from the four global products was ¥135,602 million, up 18.0% year on year. Progress in overseas expansion through information activities, disease awareness, additional indications, and demand for home treatment is noted for each product. - FY2021AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥489,837 million, up 14.0% from the previous fiscal year.」
Combined revenue from the four global products was ¥489,837 million, up 14.0% from the previous fiscal year. Progress in overseas expansion through approvals and geographic expansion, disease-awareness activities, and information activities is noted for each product. - FY2021-Q3AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥360,850 million, up 10.9% year on year.」
Combined revenue from the four global products was ¥360,850 million, up 10.9% year on year. Progress in overseas sales activities is noted, including direct-to-consumer and face-to-face information activities in the United States, Jinarc disease-awareness activities, and demand for home treatment with Lonsurf. - FY2021-Q2AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥235,975 million, up 8.0% year on year.」
Combined revenue from the four global products was ¥235,975 million, up 8.0% year on year. Overseas prescriptions and sales expanded for Jinarc, Rexulti, Lonsurf, and other products. - FY2021-Q1AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥114,918 million, up 4.3% year on year.」
Combined revenue from the four global products was ¥114,918 million, up 4.3% year on year. For Jinarc, U.S. prescriptions increased through disease-awareness and clinical-data information activities, while Lonsurf sales increased due to the expansion of countries granting approval in Europe and other factors. - FY2020AdvancedAnnual report
「In the United States, awareness of the disease and product broadened through disease-awareness activities and the provision of clinical data and other information for ADPKD treatment, and prescriptions increased steadily. Prescriptions also increased in European sales countries. As a result, revenue was ¥79,989 million, up 39.6% year on year.」
For Jinarc, disease-awareness and information activities progressed in the United States, prescriptions increased in Europe, and revenue rose 39.6% from the previous fiscal year. - FY2020-Q3AdvancedAnnual report
「In the United States, awareness of the disease and product broadened through disease-awareness activities and the provision of clinical data and other information for ADPKD treatment, and prescriptions increased steadily. Prescriptions also increased in European sales countries. As a result, revenue was ¥61,016 million, up 51.6% year on year.」
For Jinarc, disease-awareness and information activities progressed in the United States, prescriptions increased in Europe, and revenue rose 51.6% year on year. - FY2020-Q2AdvancedAnnual report
「In the United States, awareness of the disease and product broadened through disease-awareness activities and the provision of clinical data and other information for ADPKD treatment, and prescriptions increased steadily. The number of patients receiving treatment also increased in European sales countries. As a result, revenue increased substantially by 65.6% year on year to ¥40,146 million.」
For Jinarc, prescriptions increased in the United States through disease-awareness and information activities, and the number of patients receiving treatment increased in Europe, resulting in a 65.6% year-on-year increase in revenue. Overseas expansion of the four global products also continued to grow. - FY2020-Q1AdvancedAnnual report
「In the United States, awareness of the disease and product broadened through disease-awareness activities and the provision of clinical data and other information for ADPKD treatment, and prescriptions increased steadily. The number of patients receiving treatment also increased in European sales countries. As a result, revenue increased substantially by 84.7% year on year to ¥20,104 million.」
For Jinarc, prescriptions increased in the United States through disease-awareness and information activities, and the number of patients receiving treatment increased in Europe, resulting in an 84.7% year-on-year increase in revenue. - FY2019AdvancedAnnual report
「Pocari Sweat is expanding into new areas in Asia.」
In addition to expanding pharmaceutical approvals and sales in the United States, Europe, and China, Pocari Sweat is expanding into new areas in Asia. - FY2019-Q3AdvancedAnnual report
「The gastric cancer indication was approved in the United States in February 2019, Japan in August 2019, and Europe in September 2019. In China, approval was obtained in August 2019 as a treatment for colon and rectal cancer.」
Approvals for Lonsurf's gastric cancer indication and its colon and rectal cancer indication in China progressed in the United States, Japan, Europe, and China, expanding the overseas pharmaceutical business. - FY2019-Q2AdvancedAnnual report
「Sales also began successively in Europe from April 2019.」
For Rexulti, sales began successively in Europe from April 2019, advancing overseas expansion. - FY2019-Q1AdvancedAnnual report
「Contributions came from the smooth launch of the risk evaluation and mitigation strategy (REMS) for JYNARQUE, launched in the United States in May 2018 as an ADPKD treatment, and increased prescriptions resulting from disease-awareness activities. The number of patients receiving treatment also increased in European sales countries, resulting in a substantial 554.6% year-on-year increase in revenue to ¥10,883 million.」
In the United States, REMS implementation for Jinarc progressed, prescriptions increased through disease-awareness activities, and the number of patients receiving treatment also increased in Europe. - FY2018-Q3RestatedAnnual report
「The number of countries where Lonsurf is sold has steadily expanded under a licensing agreement with Servier.」
Overseas expansion continues, including the expansion of Lonsurf's sales territories, continued Jinarc sales in the United States, and increased Samsca sales in Europe and Asia. - FY2018-Q2AdvancedAnnual report
「In April 2018, Jinarc was approved in the United States as a treatment for ADPKD, and sales began in May of the same year.」
The U.S. approval and launch of Jinarc marked concrete progress in the overseas expansion of the pharmaceutical business. - FY2018-Q1AdvancedAnnual report
「The number of countries and regions selling Samsca/Jinarc had expanded to 27 worldwide, including Japan and North America.」
The number of countries and regions selling Samsca/Jinarc increased from 26 to 27. - FY2017RestatedAnnual report
「The number of countries and regions selling Samsca/JINARC had expanded to 26 worldwide, including Japan and North America.」
Samsca/JINARC was sold in 26 overseas countries and regions, with no increase from the previous quarter, while overseas expansion, including REXULTI and Lonsurf, continued. - FY2017-Q3AdvancedAnnual report
「The number of countries and regions selling Samsca/JINARC had expanded to 26 worldwide, including Japan and North America.」
The number of countries and regions selling Samsca/JINARC increased from 24 to 26. The expansion of Lonsurf's sales territories and continued REXULTI sales in Canada are also noted. - FY2017-Q2AdvancedAnnual report
「Sales began in Canada in April 2017. The number of countries and regions selling Samsca/JINARC had expanded to 24 worldwide, including Japan and North America.」
The start of REXULTI sales in Canada, the expansion of Lonsurf's sales territories, and Samsca/JINARC's presence in 24 countries and regions are noted, demonstrating concrete progress in overseas expansion. - FY2017-Q1RestatedAnnual report
「The number of countries and regions selling Samsca/JINARC had expanded to 24 worldwide, including Japan and North America.」
Samsca/JINARC was sold in 24 countries and regions, unchanged from the previous disclosure, while overseas expansion continued. The expansion of Lonsurf's sales territories is also noted. - FY2016RestatedAnnual report
「As of the end of December 2016, the number of countries where the product was sold had expanded to 24 worldwide.」
The number of countries and regions selling Samsca/JINARC for the ADPKD indication remained at 24, unchanged from the third quarter, while the overseas expansion policy continued. - FY2016-Q3AdvancedAnnual report
「As of the end of September 2016, the number of countries and regions where the product was sold had expanded to 24 worldwide.」
The number of countries and regions selling Samsca/JINARC for the ADPKD indication increased from 22 to 24. The launch of Lonsurf in European countries is also noted. - FY2016-Q2First statedAnnual report
「Samsca/JINARC, the world's first treatment for autosomal dominant polycystic kidney disease (ADPKD), a rare kidney disease, received approval in Japan in March 2014, after which understanding of the product broadened and the number of prescriptions increased. Sales as an ADPKD treatment also began in Canada and Europe in 2015, and as of the end of June 2016, the number of countries and regions where it was sold for both indications had expanded to 22 worldwide.」
In addition to expanding the sales territories for pharmaceuticals, multiple products in the nutraceuticals business are being developed in numerous countries and regions.